🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NEW! 2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Intravascular imaging guidance with OCT or IVUS during PCI in ACS is now recommended for left main or complex lesions with a class IA recommendation.

🚨 New Paper Alert! 🚨 We developed Simple hand model and Sonographer’s view to help visualize tricuspid valve anatomy and improve TEER procedural understanding. Read more: jacc.org/doi/10.1016/j.… #HandModel #TricuspidValve #Echocardiography #TEER

There is an interesting rationale behind studies testing strategies that exclude oral anticoagulation during the first month in patients with atrial fibrillation undergoing PCI, such as MATRIX-2 (evaluating single antiplatelet therapy) and WOEST-3 (evaluating DAPT). 1/4

For instance, if MATRIX-2 meets its primary endpoint, we might eventually manage these patients with one month of ticagrelor monotherapy, followed by DOAC monotherapy. That would be a significant simplification, wouldn’t it? We will see if this turns out to be the case. 4/4

4. Do these around 900 years old Sculptures at Patilana Jain Temples, Gujarat, India depict modern communication devices?

💥 AZALEA–TIMI 71 trial: less bleeding with #abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 🧐 academic.oup.com/ehjcvp/advance… #EHJPharmacotherapy 💊 EHJ-CVP Editor-in-Chief Mattia Galli 👨‍💼👨‍⚕️ European Society of Cardiology European Society of Cardiology Journals 📚

日本の心不全ガイドラインが改訂されました！ By 加藤貴雄、北井 豪 doi.org/10.1253/circj.… #circ_j #CardioX

🚨 ✨ Hot off the press! The ASPIRE study evaluating the efficacy and safety of off-label reduced-dose #apixaban in AF patients with a single dose-reduction criterion is now out in #EHJPharmacotherapy! 💊 📖 Read more: ow.ly/kJpF50VnfMp EHJ-CVP Editor-in-Chief Felice Gragnano

HOST-BR trial: After stent implantation, a three-month regimen of DAPT was more effective than a one-month regimen at reducing adverse events without increasing bleeding risk in patients with a high bleeding risk. #ACC25 Read more: bit.ly/3FLHvwW

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms,

#ACC2025: In the SMART CHOICE 3 trial, clopidogrel monotherapy was superior to Aspirin monotherapy in the longstanding phase after PCI due to a reduced risk of myocardial infarction. No difference in bleeding. Felice Gragnano PCRonline 🫀 American College of Cardiology TCTMD theheartorg | Medscape AHA Science

#ACC25 Day 2, here is the summary of today’s trials (I haven’t included the follow-up extensions of Evolut Low Risk, Triluminate, and FAME 3). Today, I counted at least 2 NEJM, 4 Lancet, 1 Nature, 1 JAMA, 1 Circulation, and 1 JACC. 1. MIGHTy-Heart = In-home paramedic visits for

📣 Clopidogrel outperforms aspirin as chronic monotherapy after PCI - better ischemic protection without increasing bleeding risk 👨‍⚕️💊 💥 P2Y12 inhibitors strike again! 💥 📌 SMART-CHOICE 3 is now online in The Lancet 👉 thelancet.com/journals/lance… Marco Valgimigli #Cardiology #ACC25

⚠️ How do we balance #bleeding & #thrombosis in patients w/ congenital bleeding disorders? 💊 New ESC consensus document in #EHJPharmacotherapy expands guidance on antithrombotic therapy in these complex cases Read more ow.ly/uq9450Vt2um EHJ-CVP Editor-in-Chief Felice Gragnano

AHA/ACC Class I 2025 ACS Recommendations In one slide: Always remember what to do!

Can we safely STOP aspirin in high bleeding risk patients after PCI? A report from the STOPDAPT-3 Trial on an Aspirin-Free Strategy in HBR patients Hirotoshi Watanabe #cardiotwitter #AHAJournals ahajrnls.org/3S9M4Ej

#EuroPCR simultaneous publication. In the 4D-ACS trial, one-month DAPT followed by prasugrel 5 mg monotherapy in ACS patients treated with a drug-coated stent reduced NACE by 49%, primarily driven by a 77% reduction in bleeding events, compared to 12-month DAPT. What I find

I could not have imagined a better way to mark this 20th anniversary than by sharing it with the many individuals who read and contribute to EuroIntervention. This milestone is not only ours—as editors, editorial team, and publishers—but belongs to the entire interventional

Giving a P2Y12 inhibitor to patients with coronary artery disease is associated with lower rates of myocardial infarction and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds this study Marco Valgimigli bmj.com/content/389/bm…

The 2025 ACS Guideline Update Endorses Ticagrelor Monotherapy ≥1 Month After DAPT Post-PCI: The Unbearable Lightness of Ticagrelor Monotherapy | JACC jacc.org/doi/full/10.10…